Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | VAV3 |
| Gene Name: | VAV3 |
| Protein Full Name: | Guanine nucleotide exchange factor VAV3 |
| Alias: | vav 3 guanine nucleotide exchange factor; Vav-3 protein |
| Mass (Da): | 97776 |
| Number AA: | 847 |
| UniProt ID: | Q9UKW4 |
| Locus ID: | 10451 |
| COSMIC ID: | VAV3 |
| Gene location on chromosome: | 1p13.3 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20401 |
| Percent of cancer specimens with mutations: | 1.05 |
| Normal role description: | Vav3 functions as a guanine nucleotide exchange factor mediating activation of Rho GTPases. Specifically, Vav3 has been shown to act as a GEF for RhoA, RhoG and RAC1. Vav3 couples the activation of growth factor type receptors such as IGFR, EGFR, PDGFR, insulin receptor, ephrin, and ROS receptor to downstream signalling molecules including but not limited to Jun kinase, NFKappa B, MAPK and Stat pathways. All of these pathways have been demonstrated to promote oncogenesis. The theory of VAV3 as an oncogene are supported by empiric evidence of VAV3 upregulation in numerous cancer systems. |